Research
Hormonal
GLP-1 receptor agonists generally do not significantly reduce diastolic blood pressure (DBP), with the exception of exenatide.
Do not expect GLP-1 medications to significantly lower your diastolic (bottom number) blood pressure, unless you are taking exenatide. Most GLP-1s primarily affect systolic pressure.
GoodRefutesHIGH confidence
Semaglutide... liraglutide... and dulaglutide... failed to reduce DBP. Exenatide modestly reduced DBP (MD: -0.94... p=0.03).
Why this rating
Meta-analysis data, though heterogeneity exists.
Source
Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
Frederick Berro Rivera et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15529
Meta-analysis · 63 studiesCited 44×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) produce a statistically significant but clinically modest reduction in systolic blood pressure (SBP) compared to placebo, with effects ranging from -1.46 to -3.40 mmHg.Good
- The magnitude of systolic blood pressure reduction with GLP-1 RAs is directly associated with changes in body weight, BMI, and HbA1c, suggesting these metabolic improvements drive the BP benefit.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →